tolllik
receptor
trigger
promis
novel
strategi
combat
cancer
induc
innat
adapt
immun
respons
bcell
lymphoma
uniqu
context
tumor
cell
express
may
harbor
latent
epsteinbarr
viru
ebv
gammaherpesviru
remark
oncogen
potenti
latent
latent
ebv
may
promot
trigger
via
suppress
lytic
ebv
elabor
initi
assess
impact
trigger
ebvposit
ebvneg
bcell
lymphoma
use
burkitt
lymphoma
bl
cell
line
vitro
model
show
independ
presenc
ebv
ligand
oligodeoxynucleotid
odn
may
may
induc
caspasedepend
cell
death
bl
cell
moreov
odn
cell
death
respons
bl
cell
associ
singlenucleotid
polymorph
snp
detect
primari
bl
tumor
peripher
blood
healthi
individu
similar
frequenc
thu
find
suggest
effect
agonist
bl
cell
test
vitro
instal
therapi
snp
bl
patient
determin
potenti
biolog
marker
therapeut
respons
treatment
target
innat
immun
tolllik
receptor
tlr
import
player
innat
immun
system
express
tlr
known
human
depend
cell
subset
differenti
statu
preferenti
express
b
cell
plasmacytoid
dendrit
cell
review
refer
iwasaki
medzhitov
synthet
ligand
short
oligodeoxynucleotid
odn
unmethyl
cpg
motif
activ
recruit
adapt
protein
myeloid
differenti
factor
induc
cascad
lead
nuclear
transloc
transcript
factor
nuclear
factor
kappalightchainenhanc
activ
b
cell
nfkb
immun
respons
follow
engag
highli
desir
cancer
treatment
synthet
agonist
regard
potenti
anticanc
agent
clinic
trial
shown
promis
result
treatment
variou
cancer
type
cpg
odn
effect
indirect
enhanc
antitumor
immun
respons
direct
induc
apoptosi
malign
cell
direct
effect
would
expect
bcell
malign
express
bcell
activ
eventu
lead
activationinduc
cell
death
cancer
cell
therefor
support
anticanc
treatment
nevertheless
agonist
effect
vari
strongli
bcell
cancer
type
respons
bcell
lymphoma
odn
show
high
variabl
thu
effect
cpg
odn
bcell
malign
predict
moreov
cpg
odn
treatment
tumorpromot
effect
benign
b
cell
strongli
enhanc
prolifer
differenti
stimul
odn
suppress
lytic
reactiv
epsteinbarr
viru
ebv
bcell
tropic
gammaherpesviru
therebi
promot
latent
ebv
latter
associ
sever
type
bcell
lymphoma
includ
burkitt
lymphoma
bl
ebv
present
nearli
case
highincid
form
bl
endem
bl
intermediateincid
case
lowincid
case
sporad
bl
bl
human
immunodefici
viru
carrier
harbor
ebv
latent
ebv
exhibit
uniqu
growth
transform
potenti
b
cell
vitro
trigger
enhanc
ebvinduc
bcell
transform
promot
latent
ebv
vitro
stimul
treatment
ebvposit
bl
could
provok
detriment
rather
benefici
outcom
singlenucleotid
polymorph
snp
associ
increas
risk
certain
bcell
lymphoma
potenti
exhibit
deregul
signal
therebi
promot
tumorigenesi
respons
snp
bcell
tumor
cpg
odn
treatment
report
use
blcell
line
model
direct
effect
stimul
malign
cell
investig
influenc
ebv
assess
impact
snp
found
primari
bl
sampl
healthi
primari
cell
trigger
alter
gene
express
activ
akata
cell
manner
cpg
odn
activ
b
cell
impact
gene
express
ask
gene
express
pattern
bl
cell
affect
trigger
use
cpg
odn
perform
microarray
analysi
compar
odn
versu
untreat
akata
cell
chang
gene
express
upregul
downregul
among
upregul
gene
mainli
interest
involv
cytokin
human
interleukin
chemokin
express
bcell
activ
transcript
nfkb
apoptosi
fa
gene
preferenti
determin
cell
prolifer
surviv
supplementari
tabl
thirteen
gene
includ
two
regul
cell
cycl
one
transcript
factor
one
involv
bcell
differenti
apoptosi
four
divers
function
four
unknown
function
show
downregul
follow
odn
treatment
supplementari
tabl
earlier
confirm
trigger
akata
cell
odn
increas
express
lead
transloc
nfkb
nucleu
valid
marker
bcell
activ
context
measur
express
flow
cytometri
express
increas
upon
odn
treatment
figur
h
express
odn
cell
increas
compar
untreat
cell
figur
b
surprisingli
control
odn
similar
odn
lack
cpg
motif
also
led
increas
express
figur
b
might
reflect
mechan
abil
control
odn
stimul
bl
cell
clarifi
point
use
akata
cell
overexpress
dominantneg
mutant
adaptor
protein
tabl
quantit
realtim
polymeras
chain
reaction
qrtpcr
confirm
activ
western
blot
data
shown
collect
valid
microarray
data
show
trigger
odn
activ
akata
cell
induc
express
moreov
result
indic
odn
use
act
manner
odn
lack
cpg
motif
activ
akata
cell
similar
extent
odn
contain
cpg
motif
explor
mechan
odninduc
cell
death
akata
cell
set
investig
whether
caspas
involv
thu
activ
odntreat
akata
cell
detect
use
luminogen
substrat
give
rise
luminesc
signal
proport
activ
trigger
ligand
h
increas
luminesc
signal
twofold
compar
trigger
increas
abolish
treatment
caspas
inhibitor
zvadfmk
figur
indic
trigger
result
increas
caspas
activ
akata
cell
activ
increas
cell
concomitantli
treat
caspas
inhibitor
find
corrobor
use
pi
stain
indic
akata
cell
death
induc
treatment
odn
abrog
caspas
inhibitor
zvadfmk
figur
western
blot
show
parp
cleavag
increas
odn
treatment
reduc
inhibitor
figur
thu
odninduc
cell
death
akata
cell
found
depend
therefor
due
apoptosi
cpg
odn
differ
consider
independ
presenc
ebv
odn
suppress
ebv
lytic
gene
express
akata
cell
primari
b
cell
promot
latent
ebv
may
provid
cell
surviv
signal
observ
akata
cell
death
upon
trigger
ask
whether
absenc
ebv
would
result
even
pronounc
cell
death
follow
trigger
henc
exogen
prevent
odn
cell
death
import
role
bcell
lymphoma
biolog
seem
act
autocrin
growth
factor
previous
report
corrobor
strong
induct
akata
cell
follow
trigger
odn
supplementari
tabl
nevertheless
treatment
result
drastic
akata
cell
death
figur
suggest
latter
could
prevent
induct
express
figur
thu
trigger
distinct
bl
cell
result
broad
rang
mrna
protein
express
level
magnitud
level
seem
independ
ebv
statu
next
determin
mrna
express
level
bl
cell
qrtpcr
although
distinct
bl
cell
show
sixfold
differ
rel
mrna
express
level
figur
odn
treatmentinduc
mrna
peak
express
level
correl
rel
mrna
express
level
figur
collect
trigger
distinct
bl
cell
result
distinct
mrna
express
link
presenc
absenc
ebv
correl
mrna
express
level
polymorph
bl
cell
might
correl
distinct
respons
trigger
polymorph
patient
link
differ
outcom
inflammatori
diseas
develop
cancer
hypothes
polymorph
could
possibl
explan
observ
thu
isol
genom
dna
bl
cell
line
analyz
presenc
polymorph
found
specif
snp
cell
line
allow
segreg
bl
cell
line
three
group
tabl
figur
suggest
distinct
blcell
respons
tlr
trigger
may
depend
snp
present
next
analyz
snp
genom
dna
primari
bl
blood
healthi
individu
inde
found
snp
detect
bl
cell
line
primari
bl
sampl
blood
healthi
individu
tabl
importantli
snp
frequenc
statist
significantli
differ
bl
cell
line
primari
bl
blood
healthi
individu
respect
suggest
direct
respons
agonist
depend
snp
could
import
factor
regard
treatment
bl
patient
trigger
analyz
effect
agonist
bl
cell
line
vitro
model
bcell
tumor
found
treatment
ligand
induc
distinct
cytokin
express
cell
death
respons
distinct
bl
cell
cell
death
depend
signal
ii
occur
concomitantli
activ
could
suppress
pan
caspas
inhibitor
iii
depend
presenc
absenc
ebv
tumor
cell
iv
associ
snp
gene
result
suggest
individu
vitro
pretest
bl
respons
cpg
odn
could
help
predict
outcom
therapeut
trigger
tailor
adjuv
molecular
treatment
bl
observ
bl
cell
differ
origin
show
distinct
cell
surviv
follow
trigger
novel
previous
demonstr
trigger
counteract
lytic
ebv
reactiv
bl
cell
promot
latent
ebv
associ
bcell
lymphoprolifer
observ
cpg
type
b
odninduc
cell
death
apoptosi
ebvposit
akata
ebvneg
cell
much
lower
extent
ebvposit
ebvneg
bl
cell
line
test
thu
ebv
statu
tumor
cell
rule
respons
bl
cell
trigger
bl
cell
consist
upregul
express
influenc
develop
growth
b
cell
act
autocrin
growth
factor
differ
bcell
lymphoma
importantli
neither
prevent
enhanc
cell
death
induc
trigger
antiinflammatori
cytokin
inhibit
immun
respons
effect
would
detriment
cancer
therapi
base
intact
enhanc
immun
respons
unintend
prolifer
malign
cell
could
provok
thu
function
cpg
type
b
odninduc
express
bl
cell
seem
consider
differ
chronic
lymphocyt
leukemia
b
cell
report
undergo
apoptosi
surprisingli
odn
induc
cell
death
extent
odn
odn
bind
contrast
lead
signal
cell
chang
secondari
structur
ectodomain
therefor
examin
whether
downstream
signal
via
involv
induct
cell
death
inde
experi
use
akata
cell
overexpress
dominantneg
mutant
indic
odn
induc
cell
death
bl
cell
manner
other
demonstr
odn
induc
cell
death
independ
cpg
motif
even
wholeodn
sequenc
anoth
pathway
trigger
cpg
odn
describ
monocyt
involv
activ
src
famili
kinas
lyn
hck
experi
bl
cell
death
induc
trigger
correl
increas
caspas
activ
caspasedepend
thu
like
due
apoptosi
bl
cell
line
test
differ
mrna
express
level
snp
mrna
express
correl
cell
death
respons
trigger
distinct
snp
role
snp
bl
unknown
start
investig
analyz
frequenc
given
snp
bl
patient
healthi
individu
found
similar
recent
report
suggest
polymorph
also
detect
confer
increas
risk
nonhodgkin
lymphoma
peopl
portug
itali
unit
state
associ
c
allel
lack
cell
death
upon
trigger
observ
mutui
bjab
bl
cell
line
strike
allow
establish
causal
link
justifi
hypothesi
distinct
cell
death
respons
upon
cpg
odn
treatment
bl
cell
may
link
snp
notabl
c
allel
exhibit
greater
nfkbbind
affin
addit
nfkb
transcript
bind
site
may
lead
increas
product
proinflammatori
cytokin
henc
presenc
c
allel
seem
result
enhanc
nfkb
activ
follow
trigger
may
lead
protect
odn
cpg
treatmentinduc
apoptosi
observ
bl
cell
without
c
allel
conclus
therapeut
trigger
appear
doubleedg
sword
may
induc
apoptosi
enhanc
lymphoprolifer
find
suggest
effect
agonist
bl
cell
test
vitro
instal
therapi
snp
bl
patient
evalu
potenti
biolog
marker
respons
treatment
target
innat
immun
cell
line
ebvposit
bl
cell
line
akata
mutui
ebvneg
bl
cell
line
akata
bjab
ramo
grown
rpmi
supplement
heatinactiv
fetal
calf
serum
streptomycin
mgml
penicillin
uml
lglutamin
mm
ebvposit
bl
akata
cell
express
dominantneg
akata
grown
medium
supplement
mgml
promega
mannheim
germani
primari
bl
tissu
sampl
peripher
blood
healthi
individu
bl
retriev
databas
institut
surgic
patholog
univers
hospit
zurich
pathopro
softwar
institut
medic
softwar
germani
bl
diagnosi
perform
accord
classif
tumor
hematopoiet
lymphoid
tissu
dna
extract
paraffinembed
wholetissu
section
accord
standard
procedur
studi
accord
swiss
law
approv
offici
author
ethic
committe
canton
zurich
peripher
blood
collect
healthi
blood
donor
age
year
randomli
select
accord
criteria
swiss
red
cross
singlenucleotid
polymorph
analysi
wholegenom
dna
extract
dneasi
blood
tissu
kit
qiagen
hombrechtikon
switzerland
accord
manufactur
instruct
genotyp
polymorph
tc
ga
done
tetraprim
assay
previous
describ
treatment
agonist
cell
split
densiti
microarray
analysi
akata
cell
mock
treat
treat
harvest
h
later
total
rna
isol
rneasi
mini
kit
qiagen
accord
manufactur
instruct
microarray
analysi
perform
function
genom
center
zurich
univers
zurich
zurich
switzerland
human
exon
st
array
chip
affymetrix
santa
clara
ca
usa
genespr
gx
softwar
agil
technolog
basel
switzerland
use
analysi
least
twofold
chang
gene
express
upregul
downregul
treat
versu
mocktreat
sampl
regard
signific
qrtpcr
taqman
total
rna
extract
cell
rneasi
kit
qiagen
dna
remov
dnafre
ambion
europ
huntingdon
cambridgeshir
uk
mg
purifi
rna
use
gener
cdna
highcapac
cdna
revers
transcript
kit
appli
biosystem
